



Re: Best-value biological medicine – Adalimumab 20 mg

4 May 2021

Dear Colleagues,

I am writing to inform you that the HSE-Medicines Management Programme (MMP) has completed an evaluation to identify a best-value biological (BVB) medicine for presentations of adalimumab 20 mg solution for injection that are available in self-administered injection devices i.e. pre-filled syringes (PFS). These presentations of adalimumab are predominately used in paediatric patients.

The MMP recommends **Amgevita® 20 mg PFS** as the BVB medicine for adalimumab 20 mg on the High Tech Arrangement. An evaluation report entitled **MMP Report BVB Medicine Adalimumab 20 mg March 2021** is available at www.hse.ie/yourmedicines in the section entitled *Best-value medicines*.

In recognition of the efficiencies that result from the prescribing of the MMP BVB medicine Amgevita® 20 mg PFS, the gain share arrangement will apply to the prescribing of this medicine. Accordingly, a once-off sum of €500 will be made available to consultant-led teams who either initiate patients on, or switch them to the MMP BVB medicine Amgevita® 20 mg PFS, with the prescription being generated on the High Tech Hub.

Further information on the BVB medicine initiative including information for healthcare professionals, and resources to support initiating patients on, or switching them to the BVB medicines are available on the MMP website (www.hse.ie/yourmedicines) in the section entitled *Best-value medicines*.

MMP pharmacists are available to engage with consultants and clinical teams to provide support for initiation of, and switching to the BVB medicines. Please contact the MMP (mmp@hse.ie) if you wish to avail of this support.

My thanks for your ongoing support in promoting safe, effective and cost-effective prescribing.

With best wishes,



Professor Michael Barry,
National Clinical Lead,
Medicines Management Programme.
www.hse.ie/yourmedicines